Trial Profile

A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with lenalidomide and 5azacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2018 Results assessing genetic biomarkers following treatment with Azacitidine or Thalidomide or Lenalidomide that predict clinical outcomes in MDS in patients enrolled in ALLG MDS3 and MDS4 clinical trials, were presented at the 109th Annual Meeting of the American Association for Cancer Research.
26 May 2017 Status changed from recruiting to completed.
15 Mar 2012 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com